Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 02/22 09:44:12 am
43.76 EUR   -0.45%
07:02aABLYNX : Announces 2017 full year results
GL
07:02aAblynx announces 2017 full year results
GL
02/16ABLYNX : 16/02/2018 ablynx announces option exercise by sanofi for t..
PU
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
02/16/2018 02/19/2018 02/20/2018 02/21/2018 02/22/2018 Date
43.84(c) 43.86(c) 43.96(c) 43.96(c) 43.74 Last
513 146 227 641 325 816 243 120 40 536 Volume
+0.27% +0.05% +0.23% 0.00% -0.50% Change
More quotes
Financials (€)
Sales 2017 55,5 M
EBIT 2017 -51,2 M
Net income 2017 -70,5 M
Finance 2017 156 M
Yield 2017 -
Sales 2018 57,1 M
EBIT 2018 -52,3 M
Net income 2018 -60,3 M
Finance 2018 92,1 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 56,6x
EV / Sales2018 56,1x
Capitalization 3 300 M
More Financials
Company
Ablynx NV is a is a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand.It offers programs for inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.The company was founded on July 4, 2001... 
More about the company
Surperformance© ratings of Ablynx
Trading Rating : Investor Rating :
More Ratings
Latest news on ABLYNX
07:02aABLYNX : Announces 2017 full year results
GL
07:02aAblynx announces 2017 full year results
GL
02/16ABLYNX : 16/02/2018 ablynx announces option exercise by sanofi for two additiona..
PU
02/16ABLYNX : Announces option exercise by sanofi for two additional multi-specific n..
GL
02/15ABLYNX : 15/02/2018 publication in accordance with article 14 of the belgian law..
PU
02/15ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
02/15ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
02/12Novo Nordisk Does Not Intend to Make a Revised Proposal for Ablynx
AQ
02/12ABLYNX : 12/02/2018 publication in accordance with article 14 of the belgian law..
PU
02/12ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
More news
Sector news : Biotechnology & Medical Research - NEC
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09:35aAblynx NV reports FY results  
07:09aABLYNX ANNOUNCES 2017 FULL YEAR RESULTS  
07:02aAblynx : ANNOUNCES 2017 FULL YEAR RESULTS  
02/16$ABLX: Ablynx announced that Sanofi (SNY) has exercised its option to license.. 
02/16Sanofi licenses two additional Nanobody candidates from Ablynx  
More tweets
Qtime:31
News from SeekingAlpha
03:35aAblynx NV reports FY results 
01/30YOUR DAILY PHARMA SCOOP : Sanofi To Acquire Ablynx, PTC Therapeutics Announces D.. 
01/22ABLYNX : Novo Offer Undervalues The Company 
01/20YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O.. 
01/17NOVO NORDISK : Don't Spoil The Ablynx Acquisition 
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 44,4 €
Spread / Average Target 1,0%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Russell G. Greig Chairman
Wim Ottevaere Chief Financial Officer
Robert K. Zeldin Chief Medical Officer
Robert Freisen Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX112.16%4 048
CELLTRION, INC.--.--%34 924
IQVIA HOLDINGS INC6.93%21 157
LONZA GROUP-7.82%19 259
INCYTE CORPORATION-6.91%18 046
NEKTAR THERAPEUTICS40.66%13 138